Building on two efficacy trials showing antiretrovirals can prevent HIV infection, discussions about this prevention strategy dominated the annual retrovirus conference
In June, Seth Berkley will relinquish his role as president and chief executive of IAVI after spending 15 years at the helm of the organization he founded in 1996. Berkley will become chief executive officer of the GAVI Alliance, a Geneva-based global health partnership launched in 2000 to increase access to immunizations, a subject that is near and dear to him. This decision, which Berkley calls “the most difficult of my life,” comes at a time when the AIDS vaccine field has been buoyed by the first evidence of vaccine efficacy in humans (coming from the RV144 trial in Thailand) and a spate of discoveries of new antibodies that scientists see as a clue for vaccine development. “It is the most exciting time we’ve ever had in the AIDS vaccine field,” Berkley says. Still, he felt it was overall the right time to make this change. “I know IAVI and the field will succeed.”
When IAVI was created, the landscape of AIDS vaccine research was much different than today. “The reason IAVI was started was because there was very little interest in AIDS vaccines from either public or private sectors. We had a fundamental belief that science could solve the problem,” he says. In 1993, less than US$160 million was being spent globally on AIDS vaccine research and development. In 2009, the global investment reached $868 million. Both IAVI and Berkley, whose passion is unwavering, deserve some of the credit for that difference.
For the past 17 years, Berkley has campaigned tirelessly to keep AIDS vaccine research on the agenda. And IAVI, which has more than 200 employees and an annual budget of approximately $87 million, has helped to advance the research and development process through its own network of laboratories, consortia, and collaborations.
Berkley’s roots in AIDS extend back to the late 1980s. Working as an epidemiologist at the Ministry of Health in Uganda, Berkley helped characterize the extent of the epidemic in that country and set up its National AIDS Control programs.
Margaret McCluskey, a senior adviser at the US Agency for International Development, called Berkley a “visionary and courageous” leader. “Seth had the insight to really partner with in-country scientists and stakeholders,” she says, “and the vision to say we have to take up the mantle to agitate and inform policy makers over the long term.”
McCluskey also credits Berkley and IAVI with trying to fill the gaps left by the work of government research agencies and the pharmaceutical industry. “He realizes the benefits of vaccines in global public health,” says McCluskey, adding that his work at GAVI will “only make it easier to roll out new vaccines, including an eventual HIV vaccine.” The GAVI Alliance has funded immunizations for more than 288 million children, saving an estimated five million lives, according to the World Health Organization. “The challenge is to get that story out and get funds for it,” says Berkley. “The other two aspects are to try to drive down the price of vaccines and also to get governments to put more of a priority on immunization.” At least initially, this will probably involve Berkley racking up even more travel miles after he relocates to Geneva with his wife and two children, ages four and six, in August. —Kristen Jill Kresge
A Phase I clinical trial known as B002, which started in February, will test the safety and immune responses induced by two HIV vaccine candidates administered either sequentially, in a prime-boost regimen, or simultaneously. One of the candidates is based on a non-infectious adenovirus serotype 35 (Ad35) vector that is used as a vehicle to deliver non-infectious fragments of HIV to the immune system. The other candidate consists of a protein administered along with an adjuvant that is intended to boost the immune responses.
Vaccinations already began at a clinical research center run by the Kenya AIDS Vaccine initiative (KAVI) in Nairobi. IAVI, the trial’s sponsor and the developer of the Ad35 candidate, has also applied for regulatory approval to conduct additional arms of the B002 trial in Lusaka, Zambia, and in Entebbe and Masaka, Uganda, and plans to enroll approximately 140 HIV-uninfected volunteers between the ages of 18 and 40. The trial is being conducted in partnership with GlaxoSmithKline (GSK; the pharmaceutical company that developed and manufactured the protein vaccine candidate), KAVI, and other partners in Africa, pending approvals.
Researchers will measure immune responses in blood samples from volunteers, as well as in genital and oral mucosal fluids collected from volunteers who agree to provide such samples. The mucosal work will be done at the clinical research center in Nairobi, says Patricia Fast, chief medical officer at IAVI.
Previous Phase I trials have shown that separately, both the Ad35 and protein candidates have acceptable safety profiles and induce immune responses against HIV. The B002 trial is the first time these two vaccine candidates will be tested in combination. “There is a lot of interest in combining vectors and proteins following on the success of RV144,” says Fast, referring to the trial conducted in Thailand that showed that a different viral vector-based/protein prime-boost regimen provided a modest 31% protection against HIV infection. —Andreas von Bubnoff
What are the challenges to understanding this protein’s structure and how would revealing its structure impact the design of possible HIV vaccine candidates?
Over the past two years, researchers have isolated nearly two dozen new antibodies against HIV from the blood of infected individuals (see VAX Oct. 2009 Spotlight article, Vaccine Research Gains Momentum). When tested in the laboratory, these antibodies are capable of inactivating or neutralizing many of the HIV strains currently in circulation and are therefore referred to as broadly neutralizing antibodies (bNAbs). Many of these bNAbs can also neutralize HIV at relatively low concentrations, suggesting they are quite potent.
Now, scientists are using these antibodies to design vaccine candidates that would ideally be able to induce similar antibodies in people before they are exposed to HIV, thereby protecting them against infection (see VAX May 2010Primer on Understanding if Broadly Neutralizing Antibodies are the Answer). However, there are several significant challenges to designing a vaccine capable of eliciting such bNAbs.
Researchers start by understanding how these antibodies successfully bind to and neutralize HIV. All of the bNAbs bind to HIV’s Envelope protein, or Env for short, which is the protein that juts out from the surface of the virus in spike-like protrusions (see image, below). By studying how they bind to HIV, researchers hope to identify the non-infectious pieces of the virus they could put into a vaccine candidate to provoke the body’s immune system to make similar antibodies. The pieces of the virus used in a vaccine to invoke an immune response are referred to as immunogens. Because the antibodies bind to the HIV Envelope spikes that dot the surface of the virus, the immunogens will likely be parts of this protein.
|HIV's Envelope Protein|
Three-dimensional image of HIV showing HIV Envelope spikes on the surface of the virus. These spikes make contact with human cells that the virus infects. The images of these spikes, which are actually three-armed structures known as trimers, were created using a technique called electron tomography that has also provided insights into how their shape changes after HIV makes contact with a human target cell. Image courtesy ofSriram Subramaniam and Donald Bliss at the US National Institutes of Health.
However, the process of selecting the pieces of HIV Envelope to put into a vaccine candidate is made more difficult by the fact that this protein is rather unstable. The HIV Envelope, also known as gp160, is actually composed of two different proteins that are weakly bound together. One of these proteins, known as gp120, is what forms the spike, and the other protein, known as gp41, is what makes up the base of the spike. Making matters even more complicated, each of the HIV Envelope spikes is actually composed of three identical gp120/gp41 proteins that are linked together. This three-pronged protein structure is referred to as the trimer.
The HIV Envelope trimer is what binds to human cells, allowing the virus to infect them. To infect human cells, the trimer spikes must be able to undergo complex changes in their conformation, and therefore they are very flexible. As a result, this trimeric protein is unstable, making it more difficult for researchers to fully understand the structure of HIV Envelope and see how some bNAbs bind to it. Researchers have been stymied by the instability and flexibility of the HIV Envelope trimer for many years. Their inability to stabilize the trimer has in turn hampered the development of AIDS vaccine candidates.
To study the structure of proteins, researchers typically use a method known as X-ray crystallography. This method involves sending a beam of X-rays through a solid, crystalline structure of the protein. This allows researchers to determine the precise arrangement of the different atoms that make up the protein, and then to determine how these atoms interact with other proteins, such as antibodies. X-ray crystallography has been used to reveal the structure of several of the key enzymes HIV uses to infect cells and reproduce.
To use X-ray crystallography to study the HIV Envelope trimer, researchers first have to be able to develop a stable crystalline structure of the trimer bound to one of the bNAbs. This has been incredibly difficult because the trimer is so unstable and flops around in space. Researchers have tried several different methods to stabilize the trimer, including adding pieces of synthetic protein into the structure to prop it up and prevent it from shifting around, but, so far, none of these attempts have stabilized the trimer enough that a pure crystal of it bound to an antibody could be obtained.
Researchers have, however, successfully crystallized a single HIV gp120/gp41 protein, which is referred to as a monomer. Some of the bNAbs that have been identified will bind to the HIV monomer, while others only bind to the trimeric HIV Envelope structure. This, plus the fact that the trimeric form of HIV Envelope is what naturally exists, makes the quest to get a crystal structure of the trimer an important goal.